ADAP Adaptimmune Therapeutics plc Stock Quote

ADAP [NASD]

Healthcare | Biotechnology | United Kingdom

Index	-	P/E	-	EPS (ttm)	-0.96	Insider Own	0.10%	Shs Outstand	154.67M	Perf Week	-12.11%
Market Cap	875.54M	Forward P/E	-	EPS next Y	-0.95	Insider Trans	132.29%	Shs Float	11.25M	Perf Month	6.25%
Income	-122.80M	PEG	-	EPS next Q	-0.23	Inst Own	80.90%	Short Float	12.77%	Perf Quarter	26.06%
Sales	3.20M	P/S	273.61	EPS this Y	-33.20%	Inst Trans	-3.87%	Short Ratio	0.91	Perf Half Y	-29.42%
Book/sh	2.43	P/B	2.45	EPS next Y	-5.60%	ROA	-33.70%	Target Price	-	Perf Year	66.20%
Cash/sh	2.72	P/C	2.19	EPS next 5Y	1.00%	ROE	-44.90%	52W Range	2.00 - 13.40	Perf YTD	10.39%
Dividend	-	P/FCF	-	EPS past 5Y	-46.40%	ROI	-113.30%	52W High	-55.30%	Beta	2.19
Dividend %	-	Quick Ratio	12.20	Sales past 5Y	-30.30%	Gross Margin	-	52W Low	199.50%	ATR	0.53
Employees	400	Current Ratio	12.20	Sales Q/Q	500.00%	Oper. Margin	-	RSI (14)	48.74	Volatility	10.14% 8.51%
Optionable	Yes	Debt/Eq	0.00	EPS Q/Q	38.70%	Profit Margin	-	Rel Volume	0.30	Prev Close	5.95
Shortable	Yes	LT Debt/Eq	0.00	Earnings	Feb 25 BMO	Payout	-	Avg Volume	1.58M	Price	5.99
Recom	2.40	SMA20	-2.21%	SMA50	6.04%	SMA200	-16.11%	Volume	446,915	Change	0.67%

Apr-22-20

Initiated

Mizuho

Neutral

Aug-02-19

Downgrade

Guggenheim

Buy → Neutral

May-31-19

Initiated

ROTH Capital

Buy

May-30-19

Resumed

Citigroup

Buy

May-07-19

Downgrade

SVB Leerink

Outperform → Mkt Perform

$12 → $5

Mar-17-17

Initiated

Wells Fargo

Market Perform

Oct-24-16

Downgrade

BofA/Merrill

Neutral → Underperform

Sep-30-16

Initiated

Raymond James

Outperform

$16

Feb-25-16

Initiated

Citigroup

Buy

$15

Jun-01-15

Initiated

Leerink Partners

Outperform

$24

Jun-01-15

Initiated

Guggenheim

Buy

Jun-01-15

Initiated

BofA/Merrill

Neutral

Feb-11-21 08:00AM	Adaptimmune to Report Fourth Quarter/ Full Year 2020 Financial Results and Business Updates on Thursday, February 25, 2021 GlobeNewswire
Feb-06-21 01:03AM	Did Adaptimmune Therapeutics' (NASDAQ:ADAP) Share Price Deserve to Gain 52%? Simply Wall St.
Dec-16-20 12:32PM	Is ADAP A Good Stock To Buy Now? Insider Monkey +6.88%
Dec-07-20 11:32PM	We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow Simply Wall St.
Nov-20-20 07:30AM	Adaptimmune to Showcase Market Potential for SPEAR T-cell Portfolio and Pipeline with Multiple Cell Therapy Platforms During Virtual Investor Day GlobeNewswire +5.30%
Nov-19-20 09:00AM	Durable Responses with ADP-A2M4 in Synovial Sarcoma with Confirmed Responses in 44% of Patients and Disease Control Rate of 94% Presented at CTOS GlobeNewswire
Nov-12-20 08:00AM	Adaptimmune to Host Virtual Investor Day on Friday, November 20th GlobeNewswire
Nov-09-20 03:18PM	Two Confirmed Responses and Five out of Six Patients with Initial Tumor Reductions from Early Dose Cohorts of SURPASS Trial, Presented at SITC GlobeNewswire
Nov-08-20 10:00AM	2 Cancer Stocks That Could Make You Filthy Rich Motley Fool
Nov-06-20 11:01AM	Adaptimmune Therapeutics PLC (ADAP) Q3 2020 Earnings Call Transcript Motley Fool
Nov-05-20 07:30AM	Adaptimmune Reports Q3 Financial Results and Business Update GlobeNewswire
06:15AM	Adaptimmune Therapeutics Plc to Host Earnings Call ACCESSWIRE
Oct-22-20 08:00AM	Adaptimmune to Report Q3 Financial Results and Business Update on Thursday, November 5, 2020 GlobeNewswire -5.08%
Oct-16-20 12:41PM	Why Adaptimmune Therapeutics Stock Is Sinking Today Motley Fool -20.13%
Oct-15-20 04:40PM	Adaptimmune Provides Full Contents of its SITC Abstract for the Phase 1 SURPASS Trial GlobeNewswire
Oct-13-20 12:04PM	Hedge Funds Have Never Been This Bullish On Adaptimmune Therapeutics plc (ADAP) Insider Monkey +10.05%
Oct-09-20 06:18AM	What Kind Of Shareholders Hold The Majority In Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Shares? Simply Wall St.
Aug-28-20 10:30AM	Promising Data from Phase 1 Trial with ADP-A2AFP in Liver Cancer at the International Liver Congress Confirm Safety Profile and Demonstrate Potential Benefit for Patients GlobeNewswire
Aug-11-20 12:00PM	All You Need to Know About Adaptimmune Therapeutics PLC (ADAP) Rating Upgrade to Buy Zacks
Aug-10-20 07:40AM	Announcing: Adaptimmune Therapeutics (NASDAQ:ADAP) Stock Soared An Exciting 367% In The Last Year Simply Wall St.
07:25AM	Did The Underlying Business Drive Adaptimmune Therapeutics' (NASDAQ:ADAP) Lovely 367% Share Price Gain? Simply Wall St.
Aug-06-20 07:30AM	Adaptimmune Reports Q2 Financial Results and Business Update GlobeNewswire -7.57%
Jul-23-20 04:00PM	Adaptimmune Granted Access to PRIority MEdicines (PRIME) Regulatory Support by the European Medicines Agency for ADP-A2M4 for the Treatment of Synovial Sarcoma GlobeNewswire -6.24%
Jul-22-20 08:00AM	Adaptimmune to Report Q2 Financial Results and Business Update on Thursday, August 6, 2020 GlobeNewswire
Jul-05-20 02:25PM	Should You Buy Adaptimmune Therapeutics plc (ADAP)? Insider Monkey
Jun-23-20 11:26AM	Edited Transcript of ADAP earnings conference call or presentation 14-May-20 12:00pm GMT Thomson Reuters StreetEvents
Jun-17-20 09:33AM	Adaptimmune Therapeutics plc (ADAP) Shares March Higher, Can It Continue? Zacks
08:52AM	How Adaptimmune Therapeutics (ADAP) Stock Stands Out in a Strong Industry Zacks
Jun-12-20 06:30AM	Is Adaptimmune Therapeutics a Buy? Motley Fool
Jun-08-20 10:30AM	Why Adaptimmune Therapeutics Stock Crushed It in May Motley Fool
Jun-04-20 10:45AM	Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares GlobeNewswire
Jun-02-20 04:37AM	Adaptimmune Announces $11/ADS Pricing; Stock Now Up Over 850% YTD SmarterAnalyst
12:38AM	Are Options Traders Betting on a Big Move in Adaptimmune Therapeutics (ADAP) Stock? Zacks
Jun-01-20 09:39PM	Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares GlobeNewswire +5.15%
12:51PM	Why Adaptimmune Therapeutics Stock Sank and Then Quickly Rebounded Today Motley Fool
11:01AM	Party Time: Brokers Just Made Major Increases To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Earnings Forecasts Simply Wall St.
09:38AM	Company News for June 1, 2020 Zacks
06:09AM	Adaptimmune's stock tumbles after plans for public stock offering MarketWatch
06:00AM	Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares GlobeNewswire
04:15AM	Adaptimmune Spikes 127% Post-ASCO; Analyst Triples Price Target SmarterAnalyst
May-29-20 05:08PM	The Dow Slipped 18 Points Because Trump Pulled His Punches on China Barrons.com +127.78%
02:20PM	Here's Why Adaptimmune Therapeutics Is Rocketing Higher Today Motley Fool
10:32AM	Traders Sift Through Virtual Cancer Meetings Winners and Losers Bloomberg
10:24AM	Adaptimmune Stock Doubles on Positive Cancer Drug Data Barrons.com
07:30AM	SPEAR T-cells Targeting MAGE-A4 Demonstrate New Responses in Esophagogastric Junction (EGJ), Lung, and Head and Neck Cancers Late Stage Development Initiated in EGJ Cancer GlobeNewswire
May-19-20 07:02AM	Where Will Adaptimmune Be in 5 Years? Motley Fool
May-14-20 12:00PM	Adaptimmune Therapeutics PLC (ADAP) Q1 2020 Earnings Call Transcript Motley Fool
08:55AM	Recap: Adaptimmune Therapeutics Q1 Earnings Benzinga
07:30AM	Adaptimmune Reports Q1 Financial Results GlobeNewswire
May-12-20 08:00AM	SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting GlobeNewswire +7.88%
06:07AM	What Kind Of Share Price Volatility Should You Expect For Adaptimmune Therapeutics plc (NASDAQ:ADAP)? Simply Wall St.
Apr-29-20 08:00AM	Adaptimmune to Report Q1 Financial Results on Thursday, May 14, 2020 GlobeNewswire +8.50%
Apr-28-20 12:00PM	What Makes Adaptimmune Therapeutics PLC (ADAP) a New Strong Buy Stock Zacks
08:00AM	Positive Opinion for Orphan Drug Designation for ADP-A2M4 in the European Union for the Treatment of Soft Tissue Sarcoma from EMA' Committee of Orphan Medicinal Products GlobeNewswire
Mar-20-20 10:40PM	Edited Transcript of ADAP earnings conference call or presentation 27-Feb-20 1:00pm GMT Thomson Reuters StreetEvents -5.42%
Mar-11-20 11:35AM	Passage Bio's IPO tops out at $248.4M after options exercised American City Business Journals
Feb-29-20 08:31AM	Earnings Update: Adaptimmune Therapeutics plc Just Reported And Analysts Are Boosting Their Estimates Simply Wall St.
Feb-27-20 07:30AM	Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update GlobeNewswire
06:00AM	Adaptimmune Therapeutics Plc to Host Earnings Call ACCESSWIRE
Feb-24-20 03:15PM	After leadership overhaul, Adaptimmune targets first cell therapy product launch American City Business Journals
Feb-20-20 04:00PM	Adaptimmune to Report Full Year / Q4 2019 Financial Results and Business Update on Thursday, February 27, 2020 GlobeNewswire
Feb-18-20 08:00AM	Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer GlobeNewswire
Feb-07-20 04:05PM	Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters Option to Purchase Additional American Depositary Shares GlobeNewswire
Feb-05-20 11:30AM	Has Adaptimmune Therapeutics (ADAP) Outpaced Other Medical Stocks This Year? Zacks +11.39%
Feb-03-20 09:13AM	Adaptimmune Therapeutics plc (ADAP) Shares March Higher, Can It Continue? Zacks
Jan-24-20 04:30PM	Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares GlobeNewswire
Jan-22-20 01:18PM	Philadelphia cell therapy company prices $84M public stock offering American City Business Journals
08:48AM	Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares GlobeNewswire
08:25AM	The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings Benzinga
06:48AM	Top Ranked Momentum Stocks to Buy for January 22nd Zacks
Jan-21-20 04:08PM	Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares GlobeNewswire -8.41%
Jan-17-20 12:00PM	What Makes Adaptimmune Therapeutics PLC (ADAP) a New Buy Stock Zacks
Jan-15-20 08:22AM	The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance Benzinga +9.90%
Jan-14-20 12:29PM	After a Massive Gain, Is There Still Room for Adaptimmune (ADAP) Stock to Soar? TipRanks
07:55AM	The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug Benzinga
02:08AM	Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies GlobeNewswire
Jan-13-20 08:30AM	Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership GlobeNewswire +200.00%
02:00AM	Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications GlobeNewswire
Dec-30-19 05:25AM	Adaptimmune Therapeutics (NASDAQ:ADAP) Will Have To Spend Its Cash Wisely Simply Wall St. -15.94%
Dec-16-19 05:45AM	Is Adaptimmune Therapeutics plc (ADAP) Going To Burn These Hedge Funds ? Insider Monkey +9.02%
Dec-03-19 02:20PM	Adaptimmune gets FDA designation to accelerate development of cancer therapy American City Business Journals +5.88%
08:30AM	Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADPA2M4 for the Treatment of Synovial Sarcoma GlobeNewswire
Nov-17-19 11:40AM	Edited Transcript of ADAP earnings conference call or presentation 6-Nov-19 1:00pm GMT Thomson Reuters StreetEvents
Nov-16-19 02:00AM	Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma GlobeNewswire
Nov-06-19 07:30AM	Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update GlobeNewswire -16.35%
Nov-01-19 08:00AM	Adaptimmune to Report Third Quarter 2019 Financial Results and Business Update on Wednesday, November 6, 2019 GlobeNewswire +9.10%
Oct-31-19 01:52PM	Is Adaptimmune Therapeutics plc (ADAP) Is Burning These Hedge Funds Insider Monkey
06:09AM	Do Directors Own Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares? Simply Wall St.
Oct-09-19 08:00AM	Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmunes Cell Therapies GlobeNewswire +6.93%
Oct-01-19 08:00AM	Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer GlobeNewswire -5.30%
Sep-30-19 08:45AM	Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO GlobeNewswire
Sep-16-19 06:41AM	Does The Adaptimmune Therapeutics plc (NASDAQ:ADAP) Share Price Fall With The Market? Simply Wall St.
Sep-10-19 09:01AM	Adaptimmune (ADAP) Gets Orphan Drug Status for T-cell Therapy Zacks +24.12%
Sep-09-19 08:00AM	United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4 GlobeNewswire +8.28%
Aug-27-19 02:11PM	Edited Transcript of ADAP earnings conference call or presentation 1-Aug-19 12:00pm GMT Thomson Reuters StreetEvents +6.99%
08:00AM	Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients GlobeNewswire
Aug-16-19 11:23AM	What's in Store for Aytu BioScience's (AYTU) Q4 Earnings? Zacks +11.64%
Aug-01-19 10:24PM	Adaptimmune Therapeutics (ADAP) Q2 2019 Earnings Call Transcript Motley Fool -10.33%
07:15AM	New Executive Team Announced at Adaptimmune GlobeNewswire
07:15AM	Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update GlobeNewswire

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It also develops ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, non-small cell lung cancer (NSCLC), esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma; ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cell; and ADP-A2M10 that is in the phase I clinical trials for the treatment of NSCLC, as well as urothelial, melanoma, and head and neck cancers. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to targets co-developing T-cell therapy. The company was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lunger John	Chief Patient Supply Officer	Jan 19	Sale	5.67	4,358	24,708	7,346	Jan 19 09:01 PM
Norry Elliot	Chief Medical Officer	Jan 19	Sale	5.67	2,111	11,968	3,539	Jan 19 09:01 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 19	Sale	5.67	9,879	56,009	13,529	Jan 19 09:00 PM
Lunger John	Chief Patient Supply Officer	Jan 12	Sale	6.15	1,058	6,509	1,767	Jan 12 09:01 PM
Bertrand William C JR	Chief Operating Officer	Jan 12	Sale	6.15	2,234	13,744	3,768	Jan 12 09:01 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 12	Sale	6.15	2,707	16,654	3,695	Jan 12 09:00 PM
Norry Elliot	Chief Medical Officer	Jan 12	Sale	6.15	841	5,174	1,396	Jan 12 09:00 PM
Bertrand William C JR	Chief Operating Officer	Jan 04	Sale	5.33	3,499	18,642	5,864	Jan 05 09:01 PM
Lunger John	Chief Patient Supply Officer	Jan 04	Sale	5.33	1,065	5,674	1,760	Jan 05 09:02 PM
Norry Elliot	Chief Medical Officer	Jan 04	Sale	5.33	845	4,502	1,392	Jan 05 09:00 PM
Rawcliffe Adrian	Chief Executive Officer	Jan 04	Sale	5.33	4,967	26,464	6,737	Jan 05 09:00 PM
Bertrand William C JR	Chief Operating Officer	Dec 14	Buy	0.69	207,000	143,824	284,808	Dec 15 09:00 PM
Wood Gavin	Chief Financial Officer	Dec 14	Buy	0.69	24,000	16,550	57,000	Dec 16 09:00 PM
Rawcliffe Adrian	Chief Executive Officer	Sep 01	Sale	8.51	2,776	23,637	3,076	Sep 02 09:00 PM
TAYTON-MARTIN HELEN KATRINA	Chief Business Officer	Aug 03	Sale	8.74	200,000	1,748,180	0	Aug 04 09:02 PM
Lunger John	Chief Patient Supply Officer	Aug 03	Sale	9.25	4,823	44,613	8,066	Aug 04 09:02 PM
Rawcliffe Adrian	Chief Executive Officer	Aug 03	Sale	9.25	2,788	25,789	3,064	Aug 04 09:01 PM
Wood Gavin	Chief Financial Officer	Jun 29	Buy	1.62	33,000	53,460	33,000	Jun 30 09:01 PM
Alleva Lawrence M	Director	Jun 09	Buy	1.89	12,900	24,381	12,900	Jun 11 09:00 PM
Noble James	Director	May 29	Sale	9.33	500,000	4,666,000	0	Jun 02 09:30 PM

open in yahoo | open in reuters | open in google

Upgrade your FINVIZ experience